The following is a summary of "Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart ...

Withdrawing renin-angiotensin inhibitors/angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists tied to higher one-year mortality, morbidity.

BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) and an ejection fraction (EF) that has improved over time. This study ...

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...

Sun Pharma Laboratories has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

Chronic kidney disease (CKD) has diverse etiologies and complex pathogenesis, and is prone to recurrent episodes and prolonged illness. In recent years, the prevalence of CKD has been increasing year ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...

Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy are among the changes put forth by KDIGO.